Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics.

ABSTRACT:

Objectives

To determine whether an expanded antigen-specific ACPA profile predicts changes in disease activity in patients with RA initiating biologics.

Methods

The study included participants from a prospective, non-randomized, observational RA cohort. For this sub-study, treatment groups of interest included biologic-naïve initiating anti-TNF, biologic-exposed initiating non-TNF, and biologic-naïve initiating abatacept. ACPAs to 25 citrullinated peptides were measured using banked enrolment serum. Principal component analysis (PCA) was performed and associations of resulting principal component (PC) scores (in quartiles) and anti-CCP3 antibody (≤15, 16-250 or >250 U/ml) with EULAR (good/moderate/none) treatment response at 6 months were examined using adjusted ordinal regr

SUBMITTER: Aripova N 

PROVIDER: S-EPMC10836988 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature